Joanna P. P.
- Country
- Poland
- Department
- Oddział Onkologii Klinicznej
Research Overview
- Randomized Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Versus Trifluridine/Tipiracil + Bevacizumab in Treated Metastatic Colorectal Cancer
- Evaluation of AZD0022 Monotherapy and Combination Therapy with Cetuximab in KRASG12D-Mutated Advanced Tumors: A Phase I/IIa Study
- Phase 2 Study of ATR Inhibitor Tuvusertib with PARP Inhibitor Niraparib or ATM Inhibitor Lartesertib in BRCA Mutant/HRD Positive Epithelial Ovarian Cancer
Data & Insights
Has run more than one trial at 21 of 87 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating various forms of solid tumors, with particular expertise in cancers harboring KRAS-G12D mutations. Their research encompasses multiple cancer types including non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
- KRAS Mutation-Driven Cancers
- Advanced Solid Tumors
- Gastrointestinal Oncology
Gynecologic Oncology
The investigator demonstrates significant involvement in treating epithelial ovarian cancer, particularly focusing on cases that have developed resistance to previous treatments. Their expertise includes managing patients who have progressed after PARP inhibitor therapy.
- Treatment-Resistant Ovarian Cancer
- Advanced Therapeutic Strategies
- Combination Treatment Approaches
Therapeutic Innovation
This clinical researcher explores novel therapeutic combinations, investigating the potential of emerging treatments such as tuvusertib in combination with other agents like niraparib and lartesertib. Their work focuses on developing more effective treatment strategies for resistant cancers.
- Novel Drug Combinations
- Targeted Therapies
- Treatment Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.